• Lexeo highlighted a cardiac gene therapy platform built on its AAVrh.10 capsid, citing 27 patients treated across two clinical programs.
• LX2006 for Friedreich ataxia cardiomyopathy: pivotal SUNRISE-FA 2 initiated; topline data expected in 2H 2027; BLA filing targeted 1H 2028.
• SUNRISE-FA 2: 26 participants; one-time 1.2x10¹² vg/kg IV dose; primary endpoint LVMi by cardiac MRI at 6 months.
• Phase I/II LX2006 data: mean LVMi fell 18% at 6 months in patients with abnormal baseline LVMi; cohorts 2-3 showed 28% reduction.
• LX2020 for PKP2 arrhythmogenic cardiomyopathy: high-dose data update expected in Q4 2026; regulatory engagement planned in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.